{"title":"Evaluation of the association between serum danger molecules at diagnosis and survival outcomes in patients with diffuse large B cell lymphoma.","authors":"Rafiye Çiftçiler, Ali Erdinc Ciftciler, Cem Selim","doi":"10.3892/mi.2025.224","DOIUrl":null,"url":null,"abstract":"<p><p>When cellular stress or tissue injury occurs, molecules known as damage-associated molecular patterns are generated. The aim of the present was to examine the association between serum danger molecules and survival outcomes in patients with diffuse large B cell lymphoma (DLBCL) at the time of diagnosis. The present study was carried out retrospectively. An evaluation was conducted on 122 patients with DLBCL who were diagnosed at a tertiary care center between 2011 and 2024. The laboratory results of the patients diagnosed with DLBCL, which were examined in detail at diagnosis, were examined retrospectively. The median age of the patients was 59 years (range, 22-87 years) and 56.6% (n=69) of the patients were female. The 5-year overall survival (OS) rates of the patients who had a fibrinogen level ≤424 mg/dl and of those who had a fibrinogen level >424 mg/dl at the time of diagnosis were 82 and 41%, respectively (P<0.001). The 5-year progression-free survival (PFS) rates of the patients with a fibrinogen level ≤424 mg/dl and of those with a fibrinogen level >424 mg/dl at the time of diagnosis were 91 and 63%, respectively (P=0.002). The 5-year OS rates of patients with a uric acid level ≤5 mg/dl and those with a uric acid level >5 mg/dl at the time of diagnosis were 74 and 44%, respectively (P=0.008). The 5-year PFS rates of patients with a uric acid level ≤5 mg/dl and those with a uric acid level >5 mg/dl at the time of diagnosis were 83 and 71%, respectively (P=0.95). On the whole, the present study demonstrates that high uric acid and fibrinogen levels are negative prognostic factors for the OS and PFS of patients with DLBCL. These data may indicate that uric acid and fibrinogen levels at the time of diagnosis may provide predictive information to the existing library of clinical risk prediction tools in DLBCL.</p>","PeriodicalId":74161,"journal":{"name":"Medicine international","volume":"5 3","pages":"25"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11904874/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicine international","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3892/mi.2025.224","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
When cellular stress or tissue injury occurs, molecules known as damage-associated molecular patterns are generated. The aim of the present was to examine the association between serum danger molecules and survival outcomes in patients with diffuse large B cell lymphoma (DLBCL) at the time of diagnosis. The present study was carried out retrospectively. An evaluation was conducted on 122 patients with DLBCL who were diagnosed at a tertiary care center between 2011 and 2024. The laboratory results of the patients diagnosed with DLBCL, which were examined in detail at diagnosis, were examined retrospectively. The median age of the patients was 59 years (range, 22-87 years) and 56.6% (n=69) of the patients were female. The 5-year overall survival (OS) rates of the patients who had a fibrinogen level ≤424 mg/dl and of those who had a fibrinogen level >424 mg/dl at the time of diagnosis were 82 and 41%, respectively (P<0.001). The 5-year progression-free survival (PFS) rates of the patients with a fibrinogen level ≤424 mg/dl and of those with a fibrinogen level >424 mg/dl at the time of diagnosis were 91 and 63%, respectively (P=0.002). The 5-year OS rates of patients with a uric acid level ≤5 mg/dl and those with a uric acid level >5 mg/dl at the time of diagnosis were 74 and 44%, respectively (P=0.008). The 5-year PFS rates of patients with a uric acid level ≤5 mg/dl and those with a uric acid level >5 mg/dl at the time of diagnosis were 83 and 71%, respectively (P=0.95). On the whole, the present study demonstrates that high uric acid and fibrinogen levels are negative prognostic factors for the OS and PFS of patients with DLBCL. These data may indicate that uric acid and fibrinogen levels at the time of diagnosis may provide predictive information to the existing library of clinical risk prediction tools in DLBCL.